Catalent has over 20 years’ experience in development, manufacturing, and analytical services for NBEs, biosimilars, and ADCs. Catalent has worked with more than 480 mAbs and 70 recombinant proteins developed, with seven marketed biosimilar products using GPEx® cell line engineering technology.
With an advanced protein improvement technology platform, and tailored solutions from DNA through commercial supply, Catalent brings better biologic treatments to clinic, faster.
Catalent’s Biologics capabilities include:
• GPEx® cell line engineering technology
• SMARTag® ADCs & bioconjugates technology
• Robust process development
• Clinical and Commercial biomanufacturing
• Comprehensive biologics analytical services
• Accelerated Biosimilar development
• Comparator sourcing
• Fill-finish and clinical supply services